Oral creatine supplementation in Duchenne muscular dystrophy: a clinical and 31P magnetic resonance spectroscopy study

Neurol Res. 2000 Mar;22(2):145-50. doi: 10.1080/01616412.2000.11741051.


The decrease in intracellular creatine concentration in Duchenne muscular dystrophy may contribute to the deterioration of intracellular energy homeostasis and may thus be one of the factors aggravating muscle weakness and degeneration. Oral creatine supplementation should have potential in alleviating the clinical symptoms. To test this hypothesis, creatine was orally administered over a period of 155 days to a 9-year-old patient with Duchenne muscular dystrophy. In accordance with previous investigations on normal subjects and trained athletes, the patient experienced improved muscle performance during creatine supplementation. Further evidence supporting this hypothesis derived from plasma creatine kinase and lactate dehydrogenase activities and repeated 31P magnetic resonance spectroscopy of the gastrocnemius muscle. These preliminary observations indicate a potential role for creatine supplementation in the symptomatic therapy of patients with muscle disease.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Child
  • Creatine / blood
  • Creatine / therapeutic use*
  • Creatine Kinase / blood
  • Exercise
  • Humans
  • Intracellular Membranes / metabolism
  • L-Lactate Dehydrogenase / blood
  • Magnetic Resonance Spectroscopy
  • Muscle, Skeletal / metabolism
  • Muscular Dystrophy, Duchenne / diagnosis
  • Muscular Dystrophy, Duchenne / drug therapy*
  • Muscular Dystrophy, Duchenne / metabolism
  • Phosphorus / metabolism
  • Phosphorus Isotopes


  • Phosphorus Isotopes
  • Phosphorus
  • L-Lactate Dehydrogenase
  • Creatine Kinase
  • Creatine